Cargando…

Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis

BACKGROUND: Accurate and fast pathogen identification and consecutive antimicrobial susceptibility testing (AST) is of vital importance for patient outcome in patients suffering from sepsis. METHODS: The Accelerate Pheno™ system is a new, fully automated, culture-independent diagnostic method for bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karrasch, Matthias, Bender, Marco, Geraci, Jennifer, Brunkhorst, Frank, Löffler, Bettina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631141/
http://dx.doi.org/10.1093/ofid/ofx163.1619
_version_ 1783269378886729728
author Karrasch, Matthias
Bender, Marco
Geraci, Jennifer
Brunkhorst, Frank
Löffler, Bettina
author_facet Karrasch, Matthias
Bender, Marco
Geraci, Jennifer
Brunkhorst, Frank
Löffler, Bettina
author_sort Karrasch, Matthias
collection PubMed
description BACKGROUND: Accurate and fast pathogen identification and consecutive antimicrobial susceptibility testing (AST) is of vital importance for patient outcome in patients suffering from sepsis. METHODS: The Accelerate Pheno™ system is a new, fully automated, culture-independent diagnostic method for both pathogen identification (ID) and antimicrobial susceptibility testing (AST). We analyzed positive blood cultures from critically ill patients with new onset of sepsis according to the new sepsis guidelines, using both conventional standard methods (VITEK, MALDI-TOF) and Accelerate Pheno™ system. ID/AST results of the Accelerate Pheno™ system were not reported to treating physicians as part of our internal evaluation process. RESULTS: Accelerate Pheno™ system correctly detected 74 pathogens [Gram-negative (GN) (n = 27), Gram-positive (GP) (n = 47)] straight out of 84 positive blood culture bottles. Gram-negative (GN) pathogens were identified as E. coli (n = 15; concordance rate 100%), K. pneumonia (n = 7; 71,4 %), S. marcescens (n = 3; 100%), E. cloacae (n = 2; 50%), P. mirabilis (n = 1; 100%) and P. aeruginosa (n = 1; 33%). Gram-positive pathogens were identified as CNS (n = 24; 82,6%), S. aureus (n = 15; 88,2%), E. faecium (n = 6; 100%) and E. faecalis (n = 2; 100%). The Accelerate Pheno™ system generated a GN-AST result in 70,4 % (19 of 27 samples) and a GP-AST result in 61,7 % (29 of 47 samples) when compared with routine AST. Growth control, analysis and mechanical failure led to reduced results in comparison to conventional ID/AST. Accelerate Pheno(TM) delivered correct MIC-results for most of the panel antibiotics [e.g., meropenem: 83,3%, gentamicin: 88,9%, ertapenem: 100%]. CONCLUSION: The use of the Accelerate Pheno™ system significantly improved time-to-ID/AST and would have led to a reduced time-to-treatment in patients suffering from sepsis if results would have been reported. The system currently has some weakness in the detection of polymicrobial and streptococcal infections but due to the short hands-on-time, culture-independence and fast generation of results, it represents a promising new diagnostic method for the consecutive antibiotic treatment of septic patients. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631141
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56311412017-11-07 Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis Karrasch, Matthias Bender, Marco Geraci, Jennifer Brunkhorst, Frank Löffler, Bettina Open Forum Infect Dis Abstracts BACKGROUND: Accurate and fast pathogen identification and consecutive antimicrobial susceptibility testing (AST) is of vital importance for patient outcome in patients suffering from sepsis. METHODS: The Accelerate Pheno™ system is a new, fully automated, culture-independent diagnostic method for both pathogen identification (ID) and antimicrobial susceptibility testing (AST). We analyzed positive blood cultures from critically ill patients with new onset of sepsis according to the new sepsis guidelines, using both conventional standard methods (VITEK, MALDI-TOF) and Accelerate Pheno™ system. ID/AST results of the Accelerate Pheno™ system were not reported to treating physicians as part of our internal evaluation process. RESULTS: Accelerate Pheno™ system correctly detected 74 pathogens [Gram-negative (GN) (n = 27), Gram-positive (GP) (n = 47)] straight out of 84 positive blood culture bottles. Gram-negative (GN) pathogens were identified as E. coli (n = 15; concordance rate 100%), K. pneumonia (n = 7; 71,4 %), S. marcescens (n = 3; 100%), E. cloacae (n = 2; 50%), P. mirabilis (n = 1; 100%) and P. aeruginosa (n = 1; 33%). Gram-positive pathogens were identified as CNS (n = 24; 82,6%), S. aureus (n = 15; 88,2%), E. faecium (n = 6; 100%) and E. faecalis (n = 2; 100%). The Accelerate Pheno™ system generated a GN-AST result in 70,4 % (19 of 27 samples) and a GP-AST result in 61,7 % (29 of 47 samples) when compared with routine AST. Growth control, analysis and mechanical failure led to reduced results in comparison to conventional ID/AST. Accelerate Pheno(TM) delivered correct MIC-results for most of the panel antibiotics [e.g., meropenem: 83,3%, gentamicin: 88,9%, ertapenem: 100%]. CONCLUSION: The use of the Accelerate Pheno™ system significantly improved time-to-ID/AST and would have led to a reduced time-to-treatment in patients suffering from sepsis if results would have been reported. The system currently has some weakness in the detection of polymicrobial and streptococcal infections but due to the short hands-on-time, culture-independence and fast generation of results, it represents a promising new diagnostic method for the consecutive antibiotic treatment of septic patients. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631141/ http://dx.doi.org/10.1093/ofid/ofx163.1619 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Karrasch, Matthias
Bender, Marco
Geraci, Jennifer
Brunkhorst, Frank
Löffler, Bettina
Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis
title Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis
title_full Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis
title_fullStr Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis
title_full_unstemmed Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis
title_short Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis
title_sort accelerating time to pathogen-adapted antibiotic treatment through culture-independent antimicrobial susceptibility testing in patients suffering from sepsis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631141/
http://dx.doi.org/10.1093/ofid/ofx163.1619
work_keys_str_mv AT karraschmatthias acceleratingtimetopathogenadaptedantibiotictreatmentthroughcultureindependentantimicrobialsusceptibilitytestinginpatientssufferingfromsepsis
AT bendermarco acceleratingtimetopathogenadaptedantibiotictreatmentthroughcultureindependentantimicrobialsusceptibilitytestinginpatientssufferingfromsepsis
AT geracijennifer acceleratingtimetopathogenadaptedantibiotictreatmentthroughcultureindependentantimicrobialsusceptibilitytestinginpatientssufferingfromsepsis
AT brunkhorstfrank acceleratingtimetopathogenadaptedantibiotictreatmentthroughcultureindependentantimicrobialsusceptibilitytestinginpatientssufferingfromsepsis
AT lofflerbettina acceleratingtimetopathogenadaptedantibiotictreatmentthroughcultureindependentantimicrobialsusceptibilitytestinginpatientssufferingfromsepsis